Nebenwirkungen · Puregon
Puregon 300 IU/0.36 mL solution for injection Puregon 600 IU/0.72 mL solution for injection Puregon 900 IU/1.08 mL solution for injection · Abschnitt 4.8 · PDF-Seite 8
HOS-085467 · Präparat HOS-083121
Treatment of males: The table below lists the adverse reactions with follitropin beta reported in a clinical trial in males (30 patients dosed) and post-marketing surveillance, according to system organ class and frequency; common (≥ 1/100 to < 1/10) and not known (cannot be estimated from available data). SOC Frequency1 Adverse reaction Immune system disorders Not known Anaphylactic reactions Nervous system disorders Common Headache Skin and subcutaneous tissue Common Acne disorders Rash Reproductive system and breast Common Epididymal cyst disorders Gynaecomastia General disorders and Common Injection site reaction2 administration site conditions 1. Adverse reactions that are reported only once are listed as common because a single report raises the frequency above 1%. 2. Local reactions at the site of injection include induration and pain.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-18T17:19:00Z · SHA-256 3fdd9364877a2ca4d9363213024887fcf6c4c693365f766eb9532291d20f6770 · Passage 31d6ec4ae6605c9354b5632fc7ad01e022be93778c9841f6c0179c513c378160 · Zeichen 3549–4799 im Abschnitt